PLCG2 and myelodysplastic syndrome: Here, PIK3CD, AKT3, and PLCG2 point mutations were correlated to and anticipated a negative clinical outcome, as all of the MDS patients included in this study that acquired the mutated cluster were also refractory to azacitidine and lenalidomide therapy at T8.